APA (7th ed.) Citation

Van den Bent, M. J., Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J. L., Mendez, J. S., . . . Cloughesy, T. F. (2023). INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. Journal of clinical oncology. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1

Chicago Style (17th ed.) Citation

Van den Bent, Martin J., et al. "INDIGO: A Global, Randomized, Double-blinded, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation." Journal of Clinical Oncology 2023. https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1.

MLA (9th ed.) Citation

Van den Bent, Martin J., et al. "INDIGO: A Global, Randomized, Double-blinded, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation." Journal of Clinical Oncology, 2023, https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA1.